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M1 and 36.1%-46.6% of M2 received second line while 25.6%-32.3% of M1 and 18.2%-
25.1% of M2 received third line. Increasing the gap to 60 days decreased the total rate 
of second line therapy slightly for M1 patients to 43.0%-51.3% and to 33.0%-45.1% 
for M2. The rate of third-line therapy was similarly lower at 23.0%-30.0% for M1 
patients and 17.3%-23.2% for M2. Increasing from a 60-day to 90-day gap resulted 
in an absolute decline in the 60-day rate of therapy of 0.8%-2.6% in second line and 
0.3%-3.1% in third line across both the M1/M2 groups. CONCLUSIONS: The data are 
in agreement between the 2 databases, and analysis by varying treatment gaps did 
not significantly impact results.
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OBJECTIVES: Develop and validate an algorithm to define statin intolerance (SI) 
in an administrative database (AD). METHODS: Adults with ≥ 1 qualifying change 
in statin therapy and ≥ 1 prior diagnosis of hyperlipidemia, hypercholesterolemia, 
or mixed dyslipidemia were identified from the AD of the Health Alliance Plan 
at Henry Ford Health System (HFHS). A sample of 1000 patients was drawn from 
the pool of eligible adults using an 80/20 ratio of patients taking a moderate- to 
low-intensity statin or a high-intensity statin at the time of qualifying change in 
therapy. Statin utilization and adverse events data were abstracted from the AD 
and the HFHS electronic medical record (EMR). Patients were stratified by high 
or low cardiovascular risk based on comorbidities, and any SI was categorized as 
absolute (AI) or titration (TI). In both the AD and the EMR, identification of SI was 
based on statin treatment patterns and potential statin-related adverse events. 
With EMR as the reference, measures of concordance (Cohen’s kappa [κ ]) and 
accuracy (sensitivity, specificity, positive predictive value [PPV]) were reported for 
AD algorithms. RESULTS: In the sample population (n= 990), any SI was identified 
in 11.5% and 14.0%, AI in 2.2% and 3.1%, and TI in 9.7% and 11.8% of patients in the 
EMR and the AD, respectively. The algorithm identifying any SI had substantial 
concordance (κ= 0.66) and good sensitivity (78.1%), but modest PPV (64.0%). The 
TI algorithm performed better (κ = 0.74, sensitivity= 85.4%, PPV= 70.1%) than the 
AI algorithm (κ = 0.40, sensitivity= 50.0%, PPV= 35.5%). Specificity was high (> 94%) 
across all 3 algorithms. In the high cardiovascular risk cohort (n= 353), the any SI 
algorithm demonstrated robust concordance (κ = 0.73) and good sensitivity (80.9%) 
and PPV (75.3%), all of which were even higher for TI. CONCLUSIONS: A conserva-
tive but comprehensive, easily implementable, and valid SI algorithm from an AD 
is available for real-world research.
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OBJECTIVES: FDA-issued safety alerts and warnings play a vital role in post-mar-
ket drug surveillance. We examine the effects of the FDA safety announcements 
for rosiglitazone and pioglitazone on the utilization of these drugs and other oral 
antidiabetics. METHODS: We link safety announcements from the FDA MedWatch 
database to Medicare drug claims (Parts D & B) from 2006 to 2010. We examine the 
timing, direction and level of demand responses to safety announcements, and 
how they differ by patients’ race/ethnicity, socioeconomic status and plan type 
(PDP vs MA-PD). We then estimate the fraction of patients that continue using an 
“alerted” medication, switch to another oral antidiabetic, or stop use altogether 
(without adding another oral medication), and how these responses differ by patient 
group and plan type. RESULTS: The demand for rosiglitazone plummeted after the 
second safety alert (in May 2007), and decreased further after a (black box) warning 
was issued (in August). After the alert, 27% to 28% of rosiglitazone users switched 
to another oral antidiabetic (predominantly pioglitazone) within 6 months of the 
alert depending on patient groups and plan type; 28% to 33% discontinued use 
of rosiglitazone, but did not add another oral antidiabetic; 38% to 44% continued 
using rosiglitazone. After the warning, the numbers were 17% to 19%, 30% to 32% 
and 49% to 52% respectively. Discontinuation rates were slightly higher among 
Hispanics (32%) and those in MA-PD plans (32%). In contrast, the demand response 
for pioglitazone was more muted, while it increased slightly after the warning (in 
August). CONCLUSIONS: The demand response to safety warnings for rosiglita-
zone was large and abrupt, and a substantial fraction of those who stopped did not 
replace it with another oral antidiabetic. The demand response was fairly constant 
across race/ethnicity, socioeconomic status, and plan type, although large responses 
raise concern about adverse health consequences.
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OBJECTIVES: Breast cancer molecular subtypes provide important prognostic infor-
mation that is useful for determining adjuvant treatment strategies; however, there 
is no evidence to indicate molecular subtypes should influence choice of surgical 
treatment. The purpose of this study is to investigate the rates of mastectomy (TM) 
versus lumpectomy (BCT) for each T-stage subgroup based on hormone receptor sta-
tus. METHODS: The SEER registry was queried for all females ages 15 – 85 diagnosed 
with stage T1 or T2 invasive breast cancer from 2010-2011. Patients were stratified 
by T-stage and race. Logistic regression was used within each stratum to compare 
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OBJECTIVES: The measurement of healthcare is increasingly based on risk-adjusted 
outcomes derived from coded comorbidities in large datasets. However inaccurate or 
haphazard assessment of risk factors for morbidity and mortality in medical record 
codes can have tremendous implications for quality improvement and healthcare 
reform. The purpose of this study is to compare the prevalence of obesity, over-
weight, tobacco use and alcohol abuse of a large administrative dataset with a 
direct data collection survey. METHODS: We used the International Classification 
of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes for four lead-
ing comorbidities in the Nationwide Inpatient Sample (NIS) to compare them with 
a direct survey in the Behavioral Risk Factor Surveillance System (BRFSS) in 2011. 
The national and state estimates and the Pearson correlation coefficient for obe-
sity, overweight, smoking and alcohol abuse between NIS and direct survey were 
calculated. RESULTS: Compared with direct participant questioning in BRFSS, NIS 
reported substantially lower prevalence of obesity, overweight, smoking and alcohol. 
The prevalence of obesity, overweight, smoking and alcohol were 27.7%, 35.8%, 20.1% 
and 18.3% in direct survey and 9.6%, 0.21%, 12.2% and 4.6% in NIS. The correlation 
between NIS and direct survey was 0.27 for obesity (p= 0.06), 0.09 for overweight 
(p= 0.55), 0.62 for smoking (p< 0.01) and 0.40 for alcohol (p< 0.01). CONCLUSIONS: 
The prevalence of obesity, tobacco smoking and alcohol abuse based on ICD-9-CM 
codes in NIS is not consistent with prevalence rates by direct questioning. Patient-
level data extraction as a part of Meaningful Use standards, rather than ICD-9-CM 
codes, would improve the accuracy of these important contributors to patient out-
comes in NIS. Ensuring accuracy of important comorbidities is critical to quality 
improvement efforts and healthcare reform policies that are based on measuring 
risk-adjusted outcomes.
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OBJECTIVES: Hemophilia-related bleeding events are difficult to quantify. Insurance 
claims’ data may capture the information, but there is no robust methodology to 
identify these events. METHODS: Using 2004-2012 Truven Health MarketScan com-
mercial claims database (coverage of > 30 million employees in th United States), we 
evaluated males under age 65 having ≥ 1 inpatient/≥ 2 outpatient claims 30-day apart 
for hemophilia A or B (ICD-9: 286.0, 286.1), and ≥ 1 pharmacy claim for clotting factors 
VIII or IX with ≥ 12 months continuous enrollment from first hemophilia treatment 
were selected. Bleeding events were identified using ICD-9 codes for hemarthrosis, 
hematoma or other acute bleeds in inpatient/outpatient claims. Hemophilia treat-
ment guidelines recommend 1-14 day treatment depending on bleeding severity. 
We explored aggregating claims within varying time windows (1, 7, 10, and 14 days) 
to capture a single bleeding event and assessed sensitivity of the time differences 
using pairwise rank correlations. RESULTS: We identified 2,425 and 269 hemophilia 
A and B patients. Using a 7-day window, average annual bleeds ((total bleeds ÷ 
patient-months)*12) among patients with ≥ 1 bleed equaled 2.31 (range: 1-33) for 
hemophilia A and 1.92 (range: 1-18) for hemophilia B. Results were similar for a 
10-day window (hemophilia A: 2.21 (1-31), hemophilia B: 1.81 (1–14)) and 14-day 
window (hemophilia A: 2.10 (1–24), hemophilia B: 1.69 (1–12) ) ). A 1-day window 
produced somewhat higher numbers (hemophilia A: 2.99 (1-66), hemophilia B: 2.72 
(1-45)), but pairwise rank correlation remained high across the four assumptions 
(coefficients ≥ 0.99, p-values < 0.01 for both disease types). Frequencies are com-
parable to a large US-based study reporting bleeds in moderately-severe patients, 
albeit smaller than studies of severe patients. CONCLUSIONS: Claims data can 
be utilized to construct stable, robust indices of bleeding events in hemophilia 
patients, permitting reliable studies of factors influencing bleeding frequency and 
healthcare burden.
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OBJECTIVES: Compare changes in patterns of care and duration of therapy result-
ing from increasing the treatment gap designating a new line of therapy in meta-
static (M) gastric cancer (GaCa). METHODS: Two large integrated claims databases 
(Pharmetrics, MarketScan) spanning July 2008 to September 2012 were used to iden-
tify patients ≥ 18 years old diagnosed and treated for GaCa. Patients were required 
to be continuously enrolled for ≥ 6 months pre- and post-diagnosis. Eligible patients 
were stratified into cohorts based on the presence and timing of metastasis (M) 
diagnosis: no metastasis (NM), ≤ 120 days (M1), and ≥ 121 days (M2). Treatment gap 
intervals were varied at ≥ 30, ≥ 60 and ≥ 90 days to indicate the start of a new line of 
chemotherapy. RESULTS: There were 6,509 (3,486 NM; 1,469 M1; 654 M2) and 3,203 
(2,004 NM; 875 M1; 324 M2) patients in each of the databases meeting all inclu-
sion criteria. Comparing the 30- and 90-day gaps, mean length of treatment (days) 
increased for M1 patients from 69.8-71.0 to 83.4-84.5 in first, 55.4-56.6 to 55.7-60.3 
in second, and 56.5-59.7 to 60.1-64.9 in third line. Using a 30-day gap, 46.4%-54.2% of 
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MEDICATION ADHERENCE STUDIES
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OBJECTIVES: Non-adherence is associated with poorer health outcomes and 
increased costs. This study evaluated the impact of a community pharmacist 
medication adherence consultation on health care costs and the risk of hospitali-
zation. METHODS: Patients initiating therapy within 16 drug classes were offered 
face-to-face or telephonic consultations by a Walgreens pharmacist between 
2/7/2013 – 10/6/2013. Consultation included motivational interviewing focused on 
fitting medication-taking behavior into patients’ daily routine, and removing bar-
riers to adherence. Patients were assigned to two groups according to the intensity 
of consultation: no consultations (NC) and ≥ 1 consultations received (CR). Patients 
were linked deterministically to the IMS Health PharMetrics Plus database such that 
6 months of pharmacy and medical claims data pre and post their index date could 
be analyzed. Cost differences from the pre to post-index periods were compared 
between NC and CR groups, using difference in differences estimation in a GLM 
model, controlling for demographic and clinical confounders. RESULTS: CR patients 
(n= 58,449) and NC patients (n= 53,870) had similar age (48.2 vs. 47.7 years), gender 
(59.0% vs. 57.7% female) and disease burden (0.61 vs. 0.58 for Charlson Comorbidity 
Index, CCI). CR patients incurred significantly lower pre- to post-index GLM-adjusted 
total health care costs (-$266/-4.3% lower, p= 0.001), comprised of lower inpatient 
(-$231, p= 0.009), lower pharmacy (-$43, p< 0.0001), and similar outpatient costs (-$36, 
p= 0.279); and had a lower probability of hospitalization (OR: 0.92, 95% CI: 0.86, 0.98, 
p= 0.009). CR patients with a CCI equal to 1-2 realized the greatest cost savings 
(-$688, p= 0.001) compared to patients with CCI= 0 (-$106, p= 0.051), and CCI≥ 3 ($575, 
p= 0.293). CONCLUSIONS: Patients receiving structured pharmacist consultations 
focused on improving medication adherence were shown to have significantly lower 
health care costs and risk of hospitalization. Ongoing studies will explore underly-
ing relationships between program participation, adherence, and impact on health 
outcomes and costs.
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OBJECTIVES: We have previously demonstrated that full adherence with ACE-
Inhibitors (ACEI) or statins in a post-myocardial infarction (MI) population is 
associated with lower rate of cardiovascular (CV) events compared to partial- or 
non-adherence. Herein, we sought to determine the direct medical costs attributable 
to partial- and non- adherence to these therapies. METHODS: Data on CV events 
and resource utilization were collected through a retrospective, nested cohort study 
in a large US insurer database. We also analyzed two national files for physician 
and non-physician unit cost weighted averages of CV events (stroke, MI, athero-
sclerosis or angina), procedures (revascularization and CV tests) and visits (emer-
gency room and outpatient CV visits). We estimated per person cost differences 
between adherence groups and the sensitivity of the Results using weighted and 
unweighted averages. A third-party payer economic perspective was adopted; all 
costs were expressed in 2014$. RESULTS: The estimated per patient weighted aver-
age annual cumulative medical costs were $5,153 for adherent, $6,470 for partially-
adherent and $6,767 for non-adherent patients. This difference was mainly driven 
by a lower rate of CV events and revascularizations for adherent patients. Applying 
referenced unweighted averages, we estimated that the MI reference unit cost was 
$4,325 higher than the weighted average cost (p< 0.001); the CV test unit cost was 
$1,010 higher than the weighted average cost (p= 0.001). Using national prevalence 
data for incident MIs and medication adherence, we project that full adherence 
may lead to annual savings of $98.2 million and $100.9 million over partial- and 
non-adherence, respectively. CONCLUSIONS: Full adherence to statins and ACEI 
was associated with reduced per patient monthly direct medical costs of $109.7 and 
$134.4 over partial- and non-adherence. Using unweighted, rather than weighted, 
averages overestimated the economic impact, indicating the importance of data 
type in such analyses. Full adherence to guideline-recommended therapies has 
tremendous cost-saving implications.
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THE EFFECT OF COST-RELATED MEDICATION NONADHERENCE ON THE 
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BACKGROUND: The sizable fraction of the elderly adults who are left without Part D 
coverage indicates there are potential barriers in taking up Part D, including infor-
mation barriers and economical barriers. Few studies have examined how cost-
related medication nonadherence (CRN) affected the willingness of taking up Part D 
among elderly adults using national representative data. OBJECTIVES: To estimate 
the impact of self-reported CRN on the decision of taking up Medicare Part D among 
Medicare beneficiaries age 65 and above who did not have Part D coverage in 2006 
incorporating the effect of complex sample survey design. METHODS: This retro-
spective cross-sectional study used data from the 2006 Health and Retirement Study 
database (2006 HRS). Information on patient demographics, social and economic 
factors and health insurance coverage were obtained by survey. The dual-eligible 
beneficiaries were excluded due to automatically enrollment. A total of 5,826 eligible 
risk of TM by hormone receptor status adjusting for age. RESULTS: Among the 
86255 women with invasive breast cancer, 38621 (45%) underwent TM, 10261 (12%) 
were Her2 positive, and 9512 (11%) were Black. For Black women with T1 tumors, 
after adjusting for age, the odds of TM were 1.3 (95% CI 1.1, 1.6) times higher for 
estrogen receptor (ER)(+) and Her2(+) tumors compared to women who were ER(+)
Her2(-), 1.4 (95% CI 1.1, 1.8) times higher for ER(+)Her2(+) compared to ER(-)Her2(-), 
and 1.4 (95% CI 1.0, 1.8) times higher for ER(-)Her2(+) compared to ER(-)Her2(-). For 
White women with T1 tumors, after adjusting for age, the odds of TM were 1.4 (95% 
CI 1.3, 1.5) times higher for ER(+)Her2(+) compared to ER(+)Her2(-), 1.1 (95% CI 1.0, 
1.2) times higher for ER(+) Her2(+) compared to ER(-)Her2(-), and 1.7 (95% CI 1.5, 1.9) 
times higher for ER(-)Her2(+) compared to ER(-)Her2(-). Similar Results were seen 
for stage T2 tumors. CONCLUSIONS: For both Black and White women with early 
stage tumors, Her2 positivity predicts TM. Further research should investigate the 
role of Her2 positivity in influencing the surgical decision-making of early stage 
breast cancer patients.
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OBJECTIVES: Although European Medicines Association approved 21 biosimilars 
from 2007-2014; the Food and Drug Administration approved its first, filgrastim, 
in 2014. Regulatory approvals require pharmacokinetic/pharmacodynamic stud-
ies and efficacy/safety trials with fewer patients and shorter durations than for 
reference biologicals. Cost savings are 20%-30%. However, uptake of biosimilars 
may be delayed since clinicians and decision makers may have concerns about 
clinically-relevant differences in effectiveness, safety, and/or immunogenicity. 
Therefore, our objective was to review published literature regarding studies 
of effectiveness, safety, immunogenicity, and costs of biosimilars versus refer-
ence biologicals. METHODS: We searched electronic databases using the term 
“biosimilar pharmaceuticals” as a major topic, with filters for English language 
and human species. Our inclusion criteria were: study design for comparison of 
biosimilars and data included in Results. We excluded editorials, in vitro stud-
ies, and descriptive summaries. RESULTS: We identified 174 articles. Inclusion/
exclusion criteria left 19 equivalence studies for the following: epoetins (n= 4, 
21.1%), filgrastims (n= 10, 52.6%), monoclonal antibodies (MABs) (n= 2, 10.5%), 
tumor necrosis factor blockers and MABs (n= 1, 5.3%), and interferon (n= 2, 10.5%). 
The median sample size was 104, but there were 3 large studies (n= 6177, n= 904, 
n= 606). Fifteen studies (79.0%) reported comparative effectiveness. Most studies 
also reported on safety (n= 12, 63.2%), immunogenicity (n= 6, 33.6%), and/or costs 
(n= 3, 15.8%). Cost studies included a budget impact model regarding potential sav-
ings from adopting biosimilars versus reference biologics for rheumatic disease, 
a model of cost savings comparing biosimilar versus reference epoetins, and a 
survey of uptake and associated cost savings from various biosimilar filgrastims 
across European Union countries. CONCLUSIONS: Most current published data 
on biosimilar equivalence focus primarily on effectiveness, evaluate relatively 
small numbers of patients, and report minimal data on safety, immunogenicity, or 
cost savings. To increase uptake, biosimilar manufacturers and regulators should 
consider conducting post-marketing surveillance research to provide additional 
data on safety, immunogenicity and costs.
HM4
HOW MUCH EVIDENCE DO WE NEED BEFORE IMPLEMENTING 
PHARMACOGENOMIC TESTING IN THE CLINIC?
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OBJECTIVES: Consensus on the evidence required to recommend clinical pharma-
cogenomic testing is unclear. A formal assessment of pharmacogenomic evidence 
levels in relation to other clinical interventions, such as avoiding drug-drug inter-
actions (DDI), may be helpful for policymakers. The objective of this study was 
to quantitatively compare the evidence levels of two contested drug-attenuating 
interactions with clopidogrel antiplatelet therapy, and assess the value of obtain-
ing additional evidence to inform clinical practice guidelines. METHODS: We 
developed analogous value of information (VOI) decision models for: (1) avoidance 
of proton pump inhibitors (PPIs) in clopidogrel patients, and (2) pharmacogenomic-
guided antiplatelet selection, both versus no intervention. Interaction-specific 
parameters and model structures were the only dissimilarities. We calculated 
the expected value of obtaining perfect information (EVPI) per patient, and the 
expected population value of obtaining additional information through future 
studies (EVSI). RESULTS: Current evidence for interaction-1 was slightly less 
uncertain (a 20% probability of making a non-optimal recommendation) than for 
interaction-2 (23%). The relative risk for cardiovascular death (conferred by con-
comitant PPI use in interaction-1, and reduced-function CYP2C19 alleles in interac-
tion-2) was the greatest source of uncertainty in both models. The expected value 
of perfect information for interaction-1 was $139 per patient, compared to $242 per 
patient for interaction-2. In simulated 10,000-patient clinical trials, the expected 
population value of future research for interaction-1 was $2 million, versus $110 
million for interaction-2. CONCLUSIONS: The evidence levels for clopidogrel DDI 
and pharmacogenomic effects appear to be fairly similar. However, the value of 
conducting future research on clopidogrel pharmacogenomics is higher because 
of greater uncertainty about the impact of pharmacogenomic testing on cardio-
vascular mortality. Our findings imply that evidence-based clinical guidelines 
for DDI and pharmacogenomic effects should be generally similar with regard to 
direction and strength of recommendation. This contrasts to some degree with 
current guidelines and drug labeling.
